On Jul. 8, 2020, the Mount Sinai Health System, Emergent BioSolutions and ImmunoTek Bio Centers announced a collaboration to develop, manufacture, and conduct clinical trials to evaluate Emergent’s COVID-19 hyperimmune globulin product, COVID-HIG, including a post-exposure prophylaxis study on health care providers at high risk of COVID-19 infection and other high-risk populations, with $34.6 million in funding from the U.S. DOD.